Table 2 Baseline demographic and clinical characteristics of participants according to the treatments

Age (years)

54 ± 8

54 ± 10

0.96

Weight (kg)

79 ± 11

77 ± 12

0.31

BMI (kg/m²)

29.3 ± 3

28.7 ± 4

0.33

WHR

0.97 ± 0.07

0.96 ± 0.07

0.46

FM (kg)

25 ± 7

24 ± 7

0.73

SBP (mmHg)

118 ± 12

117 ± 13

0.62

DBP (mmHg)

77 ± 10

76 ± 9

0.81

CAP score (dB/m)

300 ± 32

294 ± 32

0.28

IQR

10 ± 5

11 ± 5

0.32

Stiffness (kPa)

4.6 ± 1.2

4.7 ± 1.0

0.47

IQR

15 ± 6

16 ± 7

0.65

Glucose (mg/dL)

89 ± 9

91 ± 10

0.11

Insulin (mU/L)

13 ± 10

12 ± 7

0.49

HOMA-IR

2.95 ± 2.2

2.82 ± 1.7

0.69

TC (mg/dL)

191 ± 33

204 ± 31

0.018

TG (mg/dL)

118 ± 51

137 ± 83

0.10

HDL-C (mg/dL)

50 ± 11

52 ± 12

0.30

Albumin (g/dL)

4.4 ± 0.4

4.4 ± 0.5

0.95

AST (IU/L)

22 ± 11

21 ± 8

0.46

ALT (IU/L)

26 ± 23

23 ± 15

0.43

γGT (UI/L)

28 ± 22

23 ± 14

0.10

Creatinine (mg/dL)

0.85 ± 0.1

0.82 ± 0.2

0.28

CRP (mg/L)

3.7 ± 2

4.2 ± 4

0.27

Prevalence

 Gender (male, %)

56

50

0.61

 Menopause (%)

77

66

0.41

 Physical activity (%)

46

54

0.39

 Smokers (%)

39

31

0.47

 Obesity (%)

37

37

1

 Metabolic syndrome (%)

16

17

1

 Android obesity (%)

91

97

0.27

 Insulin resistance (%)

46

45

1

 Hypertension (%)

40

37

0.86

 Hyperlipidemia (%)

47

50

0.86

 Antihypertensive drugs (%)

36

31

0.72

 Antiplatelet agents (%)

11

9

0.77

 Lipid-lowering agents (%)

21

14

0.37

 Liver steatosis S1 grade (%)

14

24

0.39

 Liver steatosis S2 grade (%)

24

16

 Liver steatosis S3 grade (%)

61

60

 Liver fibrosis (%)

0

0

/